Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Merck
US Department of Justice
Farmers Insurance
Johnson and Johnson
Teva

Generated: July 17, 2019

DrugPatentWatch Database Preview

MAYZENT Drug Profile

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for MAYZENT
International Patents:129
US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 7
Patent Applications: 4
Prior Art and Litigation SupportOrder Prior Art and Litigation support for MAYZENT
DailyMed Link:MAYZENT at DailyMed
Drug patent expirations by year for MAYZENT
Generic Entry Opportunity Date for MAYZENT
Generic Entry Date for MAYZENT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for MAYZENT
1-(4-{1-[(E)-4-Cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid
A12906
BAF-312
BAF312
baf312-siponimod
BCP10335
compound 32 [PMID: 24900670]
EX-A873
GTPL9289
KIHYPELVXPAIDH-HNSNBQBZSA-N
SCHEMBL15157539
Siponimod (BAF312)
ZINC6717453

US Patents and Regulatory Information for MAYZENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp MAYZENT siponimod fumaric acid TABLET;ORAL 209884-001 Mar 26, 2019 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp MAYZENT siponimod fumaric acid TABLET;ORAL 209884-002 Mar 26, 2019 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp MAYZENT siponimod fumaric acid TABLET;ORAL 209884-001 Mar 26, 2019 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp MAYZENT siponimod fumaric acid TABLET;ORAL 209884-001 Mar 26, 2019 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Fuji
Deloitte
Fish and Richardson
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.